Literature DB >> 25994308

Aortic ¹⁸F-FDG uptake in patients suffering from granulomatosis with polyangiitis.

Michael J Kemna1, Jan Bucerius, Marjolein Drent, Stefan Vöö, Martine Veenman, Pieter van Paassen, Jan Willem Cohen Tervaert, Marinus J P G van Kroonenburgh.   

Abstract

PURPOSE: The objective of the study was to systematically assess aortic inflammation in patients with granulomatosis with polyangiitis (GPA) using (18)F-2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET)/CT.
METHODS: Aortic inflammation was studied in PET/CT scans obtained from 21 patients with GPA; 14 patients with sarcoidosis were included as disease controls, 7 patients with stage I or II head and neck carcinoma ascertained during routine clinical practice were used as healthy controls (HC) and 5 patients with large vessel vasculitis (LVV) were used as positive controls. Aortic (18)F-FDG uptake was expressed as the blood-normalized maximum standardized uptake value (SUVmax), known as the target to background ratio (mean TBRmax).
RESULTS: The mean TBRmax (interquartile range) of the aorta in patients with GPA, sarcoidosis, HC and LVV were 1.75 (1.32-2.05), 1.62 (1.54-1.74), 1.29 (1.22-1.52) and 2.03 (1.67-2.45), respectively. The mean TBRmax was significantly higher in patients suffering from GPA or LVV compared to HC (p < 0.05 and p < 0.005, respectively) and tended to be higher in patients suffering from sarcoidosis, but this did not reach statistical significance (p = 0.098). The mean TBRmax of the most diseased segment was significantly higher compared to HC [1.57 (1.39-1.81)] in LVV patients [2.55 (2.22-2.82), p < 0.005], GPA patients [2.17 (1.89-2.83), p < 0.005] and patients suffering from sarcoidosis [2.04 (1.88-2.20), p < 0.05]. In GPA patients, the mean TBRmax of the aorta was significantly higher in patients with previous renal involvement [2.01 (1.69-2.53)] compared to patients without renal involvement in the past [1.60 (1.51-1.80), p < 0.05]. Interrater reproducibility with a second reader was high (all intraclass correlation coefficients >0.9).
CONCLUSION: Patients suffering from GPA show marked aortic FDG uptake.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994308      PMCID: PMC4502318          DOI: 10.1007/s00259-015-3081-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


Granulomatosis with polyangiitis (GPA, Wegener’s) is an inflammatory disease entity affecting small to medium vessels. It is, together with microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome), characterized by the presence of antineutrophil cytoplasmic antibodies (ANCA) and they are frequently grouped together under the term ANCA-associated vasculitis (AAV) [1]. Sarcoidosis is a multisystemic disease with unknown aetiology [2]. These diseases share a common pathology of granuloma formation, although granulomas are noncaseating in sarcoidosis, while necrotizing in GPA. Positron emission tomography (PET) scanning with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is used for detecting high glucose metabolism in malignancies and infectious and autoimmune diseases [3-5]. Recent studies have shown that PET scans show abnormalities in patients with ANCA-associated vasculitis [6, 7]. Coregistration with CT allows the increased FDG uptake to be localized to the underlying anatomy. Aortic FDG uptake had been described incidentally in patients undergoing PET scanning during oncology staging and its potential to measure arterial inflammation has since been investigated [8, 9]. The use of PET scanning has sparked attention in the field of atherosclerosis as the arterial FDG uptake may be an independent predictor of cardiovascular events. Moreover, PET scanning has been evaluated and proven to be an important diagnostic tool in large vessel vasculitis (LVV) [10-13]. Measuring arterial FDG uptake has proven to be a reliable and reproducible method when values are blood-normalized, also known as the target to background ratio (TBR) [14-16]. In our previous study we observed enhanced FDG uptake in the aorta of patients with GPA [17]. Pathologically enhanced FDG uptake may have implications for classification of the patients. At present, the distribution of vessel involvement dictates the differentiation between specifically defined forms of vasculitis [18]. Our previous study did not specifically address the aortic uptake of patients in AAV and aortic uptake was merely assessed in a qualitative manner [17]. The aim of our current study is to systematically assess aortic FDG uptake in patients with AAV compared to positive controls (LVV), disease controls (sarcoidosis) and healthy controls (HC) using 18F-FDG PET/CT.

Materials and methods

Patients

Retrospectively, 21 patients with GPA according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature were included [19]. A PET scan was performed in patients with GPA during a period of suspected disease activity when other tools for evaluation of activity were inconclusive. The possibility of an active bacterial or viral infection was excluded by culture, serology and persistence of symptoms despite empirical antibiotic treatment. Previous renal involvement was determined by a renal biopsy showing pauci-immune necrotizing glomerulonephritis in the past [20]. However, the presence of haematuria in combination with red cell casts, dysmorphic erythrocytes (>10) and/or proteinuria sufficed [21]. Fourteen age- and sex-matched patients with biopsy-proven sarcoidosis according to the consensus statement on sarcoidosis of the American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) [2] were included as disease controls. The indication for a PET scan in patients with sarcoidosis was the presence of unexplained disease-related disabling symptoms that persisted for at least 1 year [4]. Seven age- and sex-matched patients in whom a PET scan was made during daily clinical practice for oncological staging of stage I or II head and neck carcinoma were included as HC. These patients had not (yet) received systemic chemotherapy or radiation therapy at the time of scanning. Lastly, five patients with giant cell arteritis (GCA) according to the 1990 criteria of the American College of Rheumatology (ACR) were included during a period of active disease as positive controls [22]. All PET scans were performed between December 2006 and March 2014 at the Maastricht University Medical Center. This study was carried out in compliance with the Helsinki Declaration; for this type of study formal consent is not required.

18F-FDG PET/CT

An 18F-FDG PET/CT scan was performed by scanning patients using a PET/CT (Gemini TF™ PET/CT, Philips Healthcare Nederland B.V., The Netherlands) scanner with time-of-flight (TOF) capability, together with a 64-slice Brilliance CT scanner. This scanner has a transverse and axial field of view (FOV) of 57.6 and 18 cm, respectively. The spatial resolution is around 5 mm. Patients were fasting for at least 6 h before the examination. In all patients blood glucose was measured to ensure that the blood glucose was below 10 mmol/l. FDG was injected intravenously and followed by physiological saline (10 ml). The injected total activity of FDG depended on the weight of the patient. The mean injected dose was 200 MBq. After a resting period of 45 min (time needed for uptake of FDG) PET and CT images were acquired from the head to the feet. A low-dose CT scan was performed without intravenous contrast and was used for attenuation correction of the PET images. The PET images were acquired in 5-min bed positions. The complete PET data set was reconstructed iteratively with a reconstruction increment of 5 mm to provide isotropic voxels. Vascular PET image analysis was performed on a Xeleris 2.0 workstation (Extended Brilliance Workspace™ V4.5.3.40140, Philips Healthcare Nederland B.V., The Netherlands) using previously described, validated and reproducible methods [14, 15, 23, 24]. Briefly, the aorta was divided into ascending, arch, descending and abdominal segments using anatomical landmarks derived from the CT scan. The aorta was demarcated as the region of interest (ROI) on each slice of the CT scan. Maximum body weight-corrected standardized uptake values (SUVmax) were derived from the pixel activity within the ROI on each slice of the PET scan. Slices were screened for nonvascular enhanced uptake in the close vicinity of the aorta that may falsely increase the SUV value, such as the heart or lymph nodes, and slices were censored if present. In addition, the mean blood FDG activity (SUVmean) was measured in the superior vena cava using an ROI of 5 mm on at least 5 slices, and the ROI was placed in the middle of the superior vena cava to ensure that no FDG uptake of the vessel wall was included. Arterial SUVmax values were blood-normalized by dividing the SUVmax of the aorta by the SUVmean of the blood pool in the vena cava, known as the TBRmax. Aortic FDG uptake was evaluated using (1) the mean TBRmax of the whole aorta, (2) the mean TBRmax of the most diseased segment, defined as the hottest slice and the adjacent slices superior and inferior to it, and (3) the proportion of active slices, defined as a slice with a TBR higher than 1.6 [25-27].

Statistical procedure

Numerical variables were expressed as mean (SD) or as median (interquartile range, IQR) and categorical variables as numbers (percentages). The Kruskal-Wallis test was used to compare quantitative measurements between more than two groups. Dunn’s multiple comparisons posttest analysis was performed to compare individual groups if a statistical difference was found in the Kruskal-Wallis test. To compare quantitative measurements between two unpaired groups, the Mann-Whitney test was performed. Continuous variables were correlated with the Spearman test. To assess interrater reliability, a second reader performed the measurements and the results were compared using the intraclass correlation coefficient (two-way random and absolute agreement). All statistical analyses were performed using GraphPad Prism version 6.04 for Windows (GraphPad Software, La Jolla, CA, USA) and SPSS statistics for Windows, version 20.0 (IBM, Armonk, NY, USA).

Results

Aortic FDG uptake using FDG PET/CT was assessed in 21 patients with GPA, 14 patients with sarcoidosis, 7 HC and 5 patients with LVV (see Table 1). In total, 89 (10), 97 (16), 97 (8) and 91 (5) slices of the aorta were evaluated in patients with GPA, sarcoidosis, HC and LVV, respectively, of which 2 (SD 4, 2.2 %), 8 (SD 8, 8.2 %), 4 (SD 5, 4.1 %) and 0 (SD 0, 0 %) slices were excluded due to adjacent nonvascular enhanced uptake. The interrater reliability with the second reader was excellent, with all intraclass correlation coefficient values higher than 0.9 (see Table 2).
Table 1

Patient characteristics at the time of scanning

GPASarcoidosisHCLVV
n 211475
Age (years)58.6 (16.8)59.6 (10.3)61.4 (13.2)67.3 (7.3)
Female14 (66.7 %)6 (42.9 %)2 (28.6 %)5 (100 %)
BMI24.4 (5.3)27.8 (4.2)24.1 (3.7)24.7 (4.1)
Overweight7 (33.3 %)10 (71.4 %)3 (42.9 %)5 (100 %)
Serum glucose5.7 (0.8)5.7 (0.9)5.7 (0.3)5.5 (0.8)
Serum creatinine84 (78–101)78 (70–97)77 (73–85)73 (58–78)
C-reactive protein6 (3–98)4 (3–6)3 (2–4)44 (5–71)
Medication
 Hypertension8 (38.1 %)7 (50 %)1 (14.3 %)1 (20 %)
 Diabetes4 (19.0 %)2 (14.3 %)0 (0 %)0 (0 %)
 Statin6 (28.6 %)5 (35.7 %)0 (0 %)0 (0 %)
 Prednisone14 (66.7 %)4 28.6 %)0 (0 %)1 (20 %)

Values are expressed as mean (SD), median (IQR) or n (%)

BMI body mass index

Table 2

Intraclass correlation coefficient values (95 % confidence interval)

SUVmax
Aorta abdominalis1.00 (1.00–1.00)
Aorta descendens0.99 (0.97–0.99)
Aortic arch0.98 (0.96–0.99)
Aorta ascendens0.97 (0.95–0.99)
Superior vena cavaa 0.90 (0.68–0.96)

aThe superior vena cava was measured as SUVmean

Patient characteristics at the time of scanning Values are expressed as mean (SD), median (IQR) or n (%) BMI body mass index Intraclass correlation coefficient values (95 % confidence interval) aThe superior vena cava was measured as SUVmean Differences were observed in the median mean TBRmax of the aorta between patients with LVV [2.03 (1.67–2.45)], patients with GPA [1.75 (1.32–2.05)], patients with sarcoidosis [1.62 (1.54–1.74)] and HC [1.29 (1.22–1.52)]. The mean TBRmax was higher in patients with LVV and GPA compared to HC (p < 0.005 and p < 0.05, respectively). The mean TBRmax tended to be higher in patients with sarcoidosis compared to HC, but this did not reach statistical significance (p = 0.098). This pattern was observed in all anatomical segments of the aorta (see Fig. 1). The median SUVmax values of the aorta were 3.47 (2.37–3.58) in patients with LVV, 1.90 (1.65–2.06) in patients with AAV, 2.03 (1.88–2.51) in patients with sarcoidosis and 1.62 (1.60–2.32) in HC. The median SUVmean values of the superior vena cava were 1.38 (1.30–1.62), 1.09 (0.81–1.30), 1.25 (1.09–1.45) and 1.34 (1.10–2.09] in patients with LVV, AAV, sarcoidosis and HC, respectively.
Fig. 1

Median TBR of SUVmax values of the aorta and anatomical segments in patients with LVV, GPA, sarcoidosis (Sar) and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005; ***p < 0.0005

Median TBR of SUVmax values of the aorta and anatomical segments in patients with LVV, GPA, sarcoidosis (Sar) and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005; ***p < 0.0005 The median mean TBRmax of the most diseased segment was significantly higher compared to HC [1.57 (1.39–1.81)] in patients with LVV [2.55 (2.22–2.82), p < 0.005], patients with GPA [2.17 (1.89–2.83), p < 0.005] and patients with sarcoidosis [2.04 (1.88–2.20), p < 0.05, see Fig. 2].
Fig. 2

Median TBR of SUVmax values of the most diseased segment of the aorta in patients with LVV, GPA, sarcoidosis and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005

Median TBR of SUVmax values of the most diseased segment of the aorta in patients with LVV, GPA, sarcoidosis and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005 The proportion of hot slices was significantly higher compared to HC [3.85 % (0–38.46)] in patients with LVV [98.85 % (72.69–100), p < 0.005] and patients with GPA [69.89 % (31.89–99.50), p < 0.05, see Fig. 3]. The proportion of hot slices was not statistically different in patients with sarcoidosis [49.17 % (34.89–75.58)] compared to HC (p = 0.21).
Fig. 3

The proportion of hot slices (defined as TBRmax > 1.6) in patients with LVV, GPA, sarcoidosis and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005

The proportion of hot slices (defined as TBRmax > 1.6) in patients with LVV, GPA, sarcoidosis and HC. The columns and brackets represent the median and IQR. *p < 0.05; **p < 0.005 In patients with GPA, the median mean TBRmax of the aorta was significantly higher in patients with previous renal involvement [2.01 (1.69–2.53)] compared to patients without renal involvement in the past [1.60 (1.51–1.80), p < 0.05, see Fig. 4]. The mean TBRmax of the aorta correlated significantly with the C-reactive protein level at the time of scanning (R = 0.42, p < 0.005).
Fig. 4

Difference in median TBR of SUVmax values of the aorta between GPA patients with renal involvement and GPA patients without renal involvement. Sar sarcoidosis. The columns and brackets represent the median and IQR. *p < 0.05

Difference in median TBR of SUVmax values of the aorta between GPA patients with renal involvement and GPA patients without renal involvement. Sar sarcoidosis. The columns and brackets represent the median and IQR. *p < 0.05

Discussion

It was demonstrated that PET scans show higher FDG uptake in the aorta in patients with AAV compared to HC. In addition, the most diseased segment was higher in patients with GPA and patients with sarcoidosis compared to HC. Moreover, the aortic uptake in GPA patients with previous renal involvement was higher compared to patients without renal involvement in the past and similar to patients with LVV. Since the accidental finding of aortic FDG uptake during oncological staging, 18F-FDG PET scanning has been advocated as an imaging tool that reflects the cellular pathology of atherosclerosis rather than the anatomical consequence [28]. The central question remains what underlying process is reflected by the enhanced FDG uptake in the aorta. Currently, the FDG uptake is thought to represent macrophage activity in inflamed intimal atherosclerotic plaques [9, 29]. Several histopathological studies have indeed shown that the intensity of FDG uptake correlates with the number of macrophages observed in the vessel wall [26, 28]. Interestingly, FDG uptake and arterial calcification rarely overlap [30]. The phenomenon of accelerated atherosclerosis is observed in various autoimmune diseases, including GPA [31]. Patients with GPA have a two- to fourfold increased relative risk of coronary artery disease as compared to control subjects, independent of classic risk factors [31]. Long-term mortality in GPA is dominated by cardiovascular events [32]. Recently we have shown that the metabolic syndrome is more prevalent in patients with AAV compared to HC [33]. More specifically, patients with AAV suffer more often from hypertension and an increased waist circumference, while the prevalence of the other criteria for the metabolic syndrome are comparable. In our current study, patients with sarcoidosis more often suffered from overweight and hypertension, while other cardiovascular risk factors were similar. The finding of enhanced aortic FDG uptake has been studied in parallel in patients with LVV [34]. The spectrum of LVV consists of Takayasu’s arteritis (TA) and GCA. FDG PET scans have been performed in both diseases and have shown high SUV values of the aorta. However, most studies concerning LVV only report the SUV value, which may not be the optimal measure to quantify FDG uptake in the aorta [9, 24, 35]. The TBRmax value has the advantage, to a certain extent, to correct for the FDG uptake in the blood. Recently an effort has been made towards an optimal semi-quantitative approach to measure arterial inflammation in LVV [16]. Interestingly, SUVmax values of the aorta were not increased in patients with GPA compared to the other patient groups (see “Supplementary material”). This has been observed in patients with GCA as well, in which the TBRmax value, but not the SUV value, was significantly higher in patients with GCA compared to HC [16]. Normalization by blood pool activity outperformed the other approaches and permitted the differentiation of patients with GCA from control patients [16]. The distribution of vessel involvement has in the past dictated the differentiation between specifically defined forms of vasculitis [18]. Cases have previously been reported with evident large vessel involvement in patients with small vessel vasculitis, thereby questioning the validity of the differentiation in vessel distribution [36]. Therefore, in the 2012 revised Chapel Hill Consensus Conference, it is noted that there is substantial overlap with respect to arterial involvement [19]. Our results support this notion, as the mean TBRmax values in patients with AAV were comparable to the values measured in patients with GCA. Does the enhanced aortic FDG uptake in our patients with GPA reflect atherosclerosis or large vessel involvement? The mean TBRmax values measured in our patients with GPA are at the high end of values observed in patients with established cardiovascular disease (see Table 3). Unfortunately, FDG uptake is not specific for processes of either disease. More importantly, should the finding of enhanced aortic FDG uptake prompt a change in treatment? Several studies have shown that the FDG uptake reduces after statin treatment [40, 38]. In addition, Mäki-Petäjä et al. have shown that anti-tumour necrosis factor-α treatment reduces aortic inflammation in patients with rheumatoid arthritis [25]. However, it is currently uncertain whether enhanced FDG uptake in the aorta should be an indication to start treatment with a statin or an immunosuppressive agent. Further research is warranted to assess the clinical significance of aortic inflammation.
Table 3

Mean TBR of the aorta in different subgroups of patients as reported in the literature

StudyDiseaseAortaAbdominalisDescendensArchAscendens
Rudd et al. (2007) [14]CVD1.30 (0.12)1.23 (0.16)1.31 (0.16)1.39 (0.18)
Rudd et al. (2009) [37]CVD1.651.651.851.95
Coulson et al. (2010) [23]COPD2.14 (0.16)22.12.2
Ex-smoker1.83 (0.20)21.951.95
MetS2.52.52.52.5
Mäki-Petäjä et al. (2012) [25]RA2.02 (0.22)
CVD1.74 (0.22)
Wu et al. (2012) [38]CVD1.83 (0.37)
Control1.49 (0.23)
Noh et al. (2013) [39]Control1.60 (0.15)
Besson et al. (2014) [16]GCA1.86 (0.45)1.95 (0.43)1.75 (0.37)
Control1.51 (0.30)1.59 (0.33)1.56 (0.33)
Kemna et al. (2015) [17]GPA1.84 (0.44)1.79 (0.43)1.86 (0.44)1.93 (0.51)2.00 (0.62)
Sarcoidosis1.65 (0.16)1.58 (0.22)1.68 (0.22)1.92 (0.53)1.73 (0.27)
Control1.36 (0.16)1.34 (0.17)1.38 (0.17)1.40 (0.22)1.41 (0.14)
GCA2.18 (0.36)2.05 (0.41)2.17 (0.33)2.10 (0.32)2.21 (0.44)

CVD cardiovascular disease, COPD chronic obstructive pulmonary disease, MetS metabolic syndrome, RA rheumatoid arthritis

Mean TBR of the aorta in different subgroups of patients as reported in the literature CVD cardiovascular disease, COPD chronic obstructive pulmonary disease, MetS metabolic syndrome, RA rheumatoid arthritis Lastly, we have shown that the mean TBRmax value of the most diseased segment of the aorta in patients with sarcoidosis was higher compared to HC, while the mean TBRmax values of the entire aorta were comparable. This suggests that patients with sarcoidosis suffer from aortic inflammation with a focal pattern but not diffuse. Systemic vasculitis in sarcoidosis is uncommon but has been described previously [41]. Our study suffers from several limitations. Due to the retrospective character of the study we were unable to assess other risk factors, such as the lipid profile. However, in a previous study these values were not elevated in our patients with AAV compared to HC [33]. Our patients with stage I or II head and neck carcinoma suffered from less cardiovascular risk factors compared to the patients with GPA and may therefore not be an ideal control group. The mean TBRmax of 1.36 ± 0.16 observed in our HC was slightly lower compared to the values reported in the literature, ranging between 1.49 and 1.60. Recent findings suggest that the pre-scan glucose levels and the circulation times were suboptimal for the evaluation of FDG uptake in the aorta [24]. In conclusion, patients with GPA showed marked FDG uptake in the aorta compared to HC. In addition, the aortic FDG uptake in GPA patients with previous renal involvement was equivalent to the aortic FDG uptake in patients with LVV. (DOCX 698 kb)
  40 in total

1.  The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis.

Authors:  Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

Review 2.  Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review.

Authors:  Giorgio Treglia; Maria Vittoria Mattoli; Lucia Leccisotti; Gianfranco Ferraccioli; Alessandro Giordano
Journal:  Clin Rheumatol       Date:  2011-08-11       Impact factor: 2.980

3.  The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers.

Authors:  Yen-Wen Wu; Hsian-Li Kao; Chi-Lun Huang; Ming-Fong Chen; Lian-Yu Lin; Yi-Chih Wang; Yen-Hung Lin; Hung-Ju Lin; Kai-Yuan Tzen; Ruoh-Fang Yen; Yu-Chiao Chi; Por-Jau Huang; Wei-Shiung Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-23       Impact factor: 9.236

4.  Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.

Authors:  R L M Mostard; S Vöö; M J P G van Kroonenburgh; J A Verschakelen; P A H M Wijnen; P J Nelemans; R J Erckens; M Drent
Journal:  Respir Med       Date:  2011-09-06       Impact factor: 3.415

5.  Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Mark Woodward; Valentin Fuster; Michael E Farkouh; Zahi A Fayad
Journal:  Circ Cardiovasc Imaging       Date:  2009-01-26       Impact factor: 7.792

6.  Metabolic syndrome in ANCA-associated vasculitis.

Authors:  Daniela R Petermann Smits; Benjamin Wilde; Makan Kianersi Adegani; Heiko de Jongh; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  Rheumatology (Oxford)       Date:  2012-11-28       Impact factor: 7.580

7.  Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Authors:  Maysoon Elkhawad; James H F Rudd; Lea Sarov-Blat; Gengqian Cai; Richard Wells; L Ceri Davies; David J Collier; Michael S Marber; Robin P Choudhury; Zahi A Fayad; Ahmed Tawakol; Fergus V Gleeson; John J Lepore; Bill Davis; Robert N Willette; Ian B Wilkinson; Dennis L Sprecher; Joseph Cheriyan
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

8.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

9.  Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis.

Authors:  Kaisa M Mäki-Petäjä; Maysoon Elkhawad; Joseph Cheriyan; Francis R Joshi; Andrew J K Ostör; Frances C Hall; James H F Rudd; Ian B Wilkinson
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

Review 10.  Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see.

Authors:  Myra S Cocker; Brian Mc Ardle; J David Spence; Cheemun Lum; Robert R Hammond; Deidre C Ongaro; Matthew A McDonald; Robert A Dekemp; Jean-Claude Tardif; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2012-12       Impact factor: 5.952

View more
  1 in total

1.  Boundaries of a systemic disease: a protean presentation of giant cell arteritis.

Authors:  António Mesquita; Lara Camara; Catarina Patrício; Vítor Brotas
Journal:  BMJ Case Rep       Date:  2020-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.